Dasiglucagon: First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

1. Advances in Pharmacotherapy for Congenital Hyperinsulinism.Paediatric drugs · 2026
   Review
2. Can Mini-Dose Glucagon Prevent Fasting-Induced Hypoglycemia and Preserve Fasting?Cureus · 2025
   Review
3. A Computational Glucoregulatory Model of Liver and Glucagon for the Evaluation of Therapeutics.ACS pharmacology & translational science · 2025
   Article
4. A Glucose-Responsive Glucagon-Micelle for the Prevention of Hypoglycemia.ACS central science · 2024
   Article
5. Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia.Patient preference and adherence · 2023
   Review
6. Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons.Diabetology & metabolic syndrome · 2022
   Article
7. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.Naunyn-Schmiedeberg's archives of pharmacology · 2022
   Review
8. New Developments in Glucagon Treatment for Hypoglycemia.Drugs · 2022
   Review
9. 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2022
   Review
10. Dasiglucagon: an effective medicine for severe hypoglycemia.European journal of clinical pharmacology · 2021
    Review
11. The Evolution of Insulin Administration in Type 1 Diabetes.Journal of diabetes mellitus · 2021
    Article
12. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.International journal of molecular sciences · 2021
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as